Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:12 PM ET 10-Q
Financial Results Flowers Foods Inc FLO

Flowers Foods Q3 2026 Results: Net Income $14.4M, Down 63.6% YoY

Flowers Foods reported a significant increase in cash and cash equivalents to $72.2 million as of October 10, 2026, compared to $12.1 million at the start of the fiscal year. The company is currently executing strategic initiatives including an ERP system upgrade and the acquisition of Simple Mills while managing risks related to independent distributor partner classifications.

Key figure
Net income $14.4M · -63.6% YoY
4:12 PM ET 8-K
Financial Results 4D Molecular Therapeutics, Inc. FDMT

4D Molecular Therapeutics Financial Results

4D Molecular Therapeutics reported Q3 2026 financial results and provided updates on its 4D-150 clinical programs, including the completion of randomization for the 4FRONT-2 Phase 3 trial in wet AMD. The company ended the quarter with $375 million in cash, which is expected to fund operations into the second half of 2028.

“Over the past quarter, 4DMT continued to progress 4D-150 as a potential backbone therapy for continuous control of VEGF-driven retinal diseases through completion of randomization in the second of two pivotal Phase 3 trials in wet AMD.”

David Kirn, MD, Co-founder, President and Chief Executive Officer
4:12 PM ET 8-K
Financial Results Pliant Therapeutics, Inc. PLRX

Pliant Therapeutics Financial Results

Pliant Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting strong enrollment in its Phase 1b FORTIFY trial for PLN-101095. The company ended the quarter with $388.5 million in cash and equivalents, providing a projected cash runway into 2027. Key operational milestones included preclinical data for its integrin-mediated drug delivery platform and leadership appointments in medical and research roles.

Term
Q3 2026

“The third quarter reflected continued strong execution across the Organization, including robust FORTIFY enrollment and compelling proof-of-concept data generated from our integrin-mediated drug delivery platform.”

Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant
4:12 PM ET 10-Q
Financial Results Evommune, Inc. EVMN

Evommune Q3 2026 Results: Net Loss of $30.9M, Loss Widens

For the nine months ended September 30, 2026, Evommune, Inc. reported a net loss of $84.8 million, more than double the $40.6 million loss in the prior year period, primarily driven by increased research and development and general and administrative expenses. Total assets grew to $278.3 million as of September 30, 2026, supported by cash and investments totaling approximately $262.3 million.

Key figure
Net loss $30.9M
4:12 PM ET 8-K
Financial Results Macrogenics Inc MGNX

Macrogenics Financial Results

MacroGenics reported third quarter 2026 financial results, highlighting a cash position of $287.7 million and a cash runway extending through 2028. The company achieved several clinical milestones, including completing Phase 1 dose escalation for MGC028 and dosing the first patient in the Phase 1 study of MGC030.

Term
Q3 2026

“MacroGenics has made significant progress over the past year. We have strengthened our business, sharpened our pipeline development priorities, delivered on key strategic objectives and generated approximately $290 million in non-dilutive capital over the past 12 months.”

Eric Risser, President and Chief Executive Officer

“Looking ahead, we believe MacroGenics is well positioned for a year of important milestones in 2027, with multiple opportunities to demonstrate the potential of our innovative pipeline while maintaining a disciplined approach to capital allocation.”

Eric Risser, President and Chief Executive Officer
4:11 PM ET 8-K
Financial Results Alumis Inc. ALMS

Alumis Financial Results

Alumis Inc. reported third quarter 2026 financial results and confirmed it remains on track to submit a New Drug Application (NDA) for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026. The company ended the quarter with $344.4 million in cash and cash equivalents, which is expected to fund operations into 2027.

Term
Q3 2026

“Each additional readout from the ONWARD program has strengthened the consistent body of evidence supporting envudeucitinib’s highly competitive profile in moderate-to-severe plaque psoriasis. The new data presented in October showed early and durable improvement across scalp disease severity, itch resolution, and quality of life measures, building on a 54% PASI 100 response rate observed at 48 weeks of treatment. Our fourth-quarter 2026 NDA submission remains on track.”

Martin Babler, President and Chief Executive Officer of Alumis
4:11 PM ET 8-K
Financial Results Cibus, Inc. CBUS

Cibus Financial Results

Cibus, Inc. reported financial results for the third quarter of 2026, highlighting progress in its rice herbicide-tolerance traits and the initiation of manufacturing for its first two biofragrance products. The company reduced its year-to-date cash usage by 19% year-over-year and expects to exit 2026 with an annualized net cash usage run rate of approximately $35 million.

Term
Q3 2026

“Three months ago I described three ways our platform creates value: platform programs that generate revenue today, royalties as our traits reach acres, and partnerships that deepen over time. Each of these moved closer this quarter. We received requests from our customer for larger quantities of two biofragrance products to advance their product development. Our Rice traits performed well in Latin American field trials and are now being tested where it counts, in our customer Interoc's own varieties in its own fields. Further, a second partner-funded crop program, Mustard in India, began work in the quarter.”

Craig Wichner, Chief Executive Officer
4:11 PM ET 10-Q
Financial Results Candel Therapeutics, Inc. CADL

Candel Therapeutics Q3 2026 Results: Net Loss of $21.9M, Loss Widens

Candel Therapeutics reported a significant increase in cash and cash equivalents to $203.1 million as of September 30, 2026, primarily driven by $142.6 million in net proceeds from public and at-the-market equity offerings. However, the company experienced a substantial increase in net loss to $69.6 million for the first nine months of 2026, compared to $8.7 million in the prior year, largely due to higher R&D spending and a negative swing in the fair value of warrant liabilities.

Key figure
Net loss $21.9M
4:11 PM ET 8-K
Financial Results LifeMD, Inc. LFMD

LifeMD Financial Results

LifeMD reported Q3 2026 revenue of $44.6 million and a GAAP net loss of $5.2 million, while improving adjusted EBITDA sequentially by $3.1 million. The company also announced it secured a $12.5 million senior secured term loan from Avenue Venture Opportunities Fund II and Avenue Growth Lending Fund to replace its previous credit facility.

Term
Q3 2026

“We ended the quarter with approximately 350,000 active subscribers, up 13% from a year ago and nearly flat from the second quarter, despite spending $9.5 million less on marketing. We’re helping more people access high-quality healthcare, and we’re getting more efficient at doing it. From May to September, cost per acquisition fell 32% while monthly media spend declined 45%. Adjusted EBITDA improved approximately $3.1 million sequentially to roughly breakeven, and we expect to sustain or improve these unit economics going forward.”

Justin Schreiber, Chairman and CEO of LifeMD

“Revenue of $44.6 million was below our guidance, and we are resetting our outlook for the fourth quarter and full year. We deliberately reduced marketing spend and prioritized longer patient commitments, and our partnerships took longer to ramp than we expected. Those factors weighed on revenue this quarter, but we believe our decisions put us in a stronger position to grow profitably.”

Justin Schreiber, Chairman and CEO of LifeMD
4:11 PM ET 8-K
Financial Results Ascend Wellness Holdings, Inc. AAWH

Ascend Wellness Holdings Financial Results

Ascend Wellness Holdings reported Q3 2026 net revenue of $130.0 million, a 4.2% year-over-year increase, driven by record retail transaction volumes. The company generated $31.1 million in Adjusted EBITDA and ended the quarter with 56 retail stores, subsequently expanding to 61 locations. Management highlighted strong operating leverage and positive cash flow from operations despite a significant semi-annual interest payment.

Term
Q3 2026

“Our third quarter results demonstrate the strength of our retail platform and the growing demand for our brands. We achieved record transaction volume and expanded our footprint ahead of schedule, positioning Ascend for continued growth as we optimize our operations and prepare for potential regulatory shifts in the industry.”

John Redman, CEO
4:11 PM ET 10-Q
Financial Results Hour Loop, Inc HOUR

Hour Loop Q3 2026 Results: Net Income $422K, Down 20.5% YoY

Hour Loop, Inc. reported net income of $2.30 million for the nine months ended September 30, 2026, on revenues of $95.95 million, representing an 11% revenue increase year-over-year. Despite higher sales, net income slightly decreased from $2.36 million in the prior year period due to increased cost of revenues and selling expenses.

Key figure
Net income $422K · -20.5% YoY
4:11 PM ET 8-K
Financial Results Relmada Therapeutics, Inc. RLMD

Relmada Therapeutics Financial Results

Relmada Therapeutics reported third quarter 2026 financial results and provided a corporate update on its NDV-01 and sepranolone programs. The company ended the quarter with $202.1 million in cash, which is expected to fund operations through 2029, and remains on track to submit an IND for NDV-01 by year-end 2026.

“Relmada has made significant progress in advancing the NDV-01 CMC program and remains on track to submit the NDV-01 IND by year-end 2026. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through the completion of the Phase 3 SPECTRUM program.”

Sergio Traversa, Chief Executive Officer of Relmada Therapeutics

“Initial 18-month results from the ongoing NDV-01 Phase 2 study demonstrate extended durability of complete response and continued favorable tolerability. Our Phase 3 program remains unchanged, with two independent registrational pathways in NMIBC, and we have renamed it SPECTRUM to reflect the potential breadth of NDV-01 across the NMIBC disease spectrum. We expect to begin the SPECTRUM program upon IND clearance.”

Bipin Dalmia, Chief Business Officer of Relmada Therapeutics
4:11 PM ET 8-K
Financial Results OptimumBank Holdings, Inc. OPHC

OptimumBank Holdings Financial Results

OptimumBank Holdings reported Q3 2026 net income of $7.2 million, or $0.30 per diluted share, representing a 67% increase in EPS compared to the prior year. The company saw strong balance sheet growth with the gross loan portfolio increasing 12.3% sequentially to $1.37 billion and total deposits rising 10.6% to $1.34 billion.

Term
Q3 2026
4:11 PM ET 8-K
Financial Results Fluent, Inc. FLNT

Fluent Financial Results

Fluent, Inc. reported Q3 2026 revenue of $53.6 million, a 14% increase year-over-year, driven by a 100% growth in its Commerce Media Solutions segment. The company significantly reduced its net loss to $3.1 million from $7.6 million in the prior year and achieved breakeven Adjusted EBITDA.

Term
Q3 2026

“The third quarter was another strong quarter for us, driven by the continued growth of Commerce Media Solutions, which now represents 70% of our revenue and is operating at an annual revenue run rate that exceeds $145 million. Revenue from our aggregate continuing businesses grew 29% year-over-year in the third quarter, an acceleration from 25% in the second quarter. Commerce Media Solutions continues to reshape the profile of our Company. It is driving our growth, improving the quality of our revenue, and was a key contributor to delivering near-breakeven adjusted EBITDA this quarter.”

Don Patrick, Chief Executive Officer

“We continue to add new partners to our network, and we’re highly encouraged by the demand we’re seeing for our commerce media offerings across the markets we serve. As our revenue mix improves and our margin profile strengthens, we believe we are well positioned to close out a strong year. We remain confident in delivering full-year double-digit revenue growth on our aggregate continuing businesses with improved full-year adjusted EBITDA.”

Don Patrick, Chief Executive Officer
4:11 PM ET 8-K
Financial Results GrabAGun Digital Holdings Inc. PEW

GrabAGun Digital Holdings Financial Results

GrabAGun Digital Holdings reported Q3 2026 net revenues of $21.2 million, a 4.7% decrease year-over-year due to lower product sales. Despite the revenue dip, gross profit increased 44% and gross margin expanded 480 basis points to 14.4%, driven by improved sourcing and disciplined purchasing.

Term
Q3 2026

“Our third-quarter results reflect the progress we are making in improving the quality and profitability of our business. Gross profit increased 44% and gross margin expanded 480 basis points to 14.4%, primarily driven by average selling prices and supported by better sourcing, a stronger product cost basis and disciplined purchasing.”

Marc Nemati, Chairman and Chief Executive Officer

“Subsequent to quarter end, we completed the acquisition of Camfour, a New England-based wholesale distributor funded entirely with cash on hand and without financing or issuing shares. We believe combining Camfour's distribution capabilities with our e-commerce and logistics platform will stimulate growth, expand our customer base and improve our purchasing economics.”

Marc Nemati, Chairman and Chief Executive Officer
4:11 PM ET 8-K
Financial Results United States Antimony Corp UAMY

United States Antimony Financial Results

United States Antimony Corp reported Q3 2026 revenue of $10.1 million, a 16% increase year-over-year, driven by a 68% surge in antimony pounds sold. Despite a 113% increase in gross profit to $4.3 million, the company reported a net loss of $9.5 million, impacted by non-cash stock-based compensation and an unrealized loss on its Larvotto Resources investment.

Term
Q3 2026
4:11 PM ET 8-K
Financial Results Equillium, Inc. EQ

Equillium Financial Results

Equillium reported third quarter 2026 financial results, highlighting the initiation of a Phase 1 clinical trial for EQ504 with proof-of-mechanism data expected in Q2 2027. The company strengthened its balance sheet with a $20 million financing tranche closed in October 2026, extending its cash runway into 2029.

“We continue to make important progress advancing EQ504, with the recent initiation of clinical development marking a significant milestone for the program. We believe EQ504’s differentiated immunoregulatory mechanism of action, without broad immune suppression, has the potential to address key epithelial and immune pathways involved in inflammatory disease.”

Bruce Steel, Chief Executive Officer of Equillium

“We look forward to reporting proof-of-mechanism data in the second quarter of 2027, which we expect will inform our planned proof-of-concept study in ulcerative colitis that we expect to initiate in the second half of 2027. Supported by our strong financial position, we remain focused on advancing EQ504 to patients while continuing to evaluate its broader therapeutic potential.”

Bruce Steel, Chief Executive Officer of Equillium
4:11 PM ET 8-K
Financial Results Sanara MedTech Inc. SMTI

Sanara MedTech Financial Results

Sanara MedTech reported Q3 2026 net revenue of $28.4 million, an 8% increase year-over-year, and Adjusted EBITDA of $5.6 million. The company recorded a net loss from continuing operations of $1.3 million, which included $3.0 million in legal and advisory costs related to its pending merger with MiMedx Group, Inc.

Term
Q3 2026
4:11 PM ET 10-Q
Financial Results Pliant Therapeutics, Inc. PLRX

Pliant Therapeutics Q3 2026 Results: Net Loss of $24.4M, Loss Narrows

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on integrin-based therapeutics, with its lead candidate PLN-101095 currently in Phase 1a/1b trials. The company reports significant net losses since inception and expects to require substantial additional capital to fund its ongoing research and development activities.

Key figure
Net loss $24.4M
4:11 PM ET 10-Q
Financial Results Rhinebeck Bancorp, Inc. RBKB

Rhinebeck Bancorp Q3 2026 Results: Net Income $3.15M, Up 17.0% YoY

Rhinebeck Bancorp, Inc. reported net income of $3.15 million for the quarter ended September 30, 2026, compared to $2.70 million in the prior year period. The company completed its conversion to a fully public company on July 21, 2026, resulting in a significant increase in total stockholders' equity to $220.8 million.

Key figure
Net income $3.15M · +17.0% YoY
4:11 PM ET 10-Q
Financial Results Socket Mobile, Inc. SCKT

Socket Mobile Q3 2026 Results: Net Loss of $789K, Loss Narrows

Socket Mobile reported a 9% increase in Q3 2026 revenue to $3.39 million, though year-to-date revenue remains down 8.9% compared to 2025. The company continues to operate at a loss, reporting a net loss of $0.79 million for the quarter and $3.04 million for the first nine months of 2026, as it manages high operating expenses relative to gross profit.

Key figure
Net loss $789K
4:11 PM ET 8-K
Financial Results Eledon Pharmaceuticals, Inc. ELDN

Eledon Pharmaceuticals Financial Results

Eledon Pharmaceuticals reported third quarter 2026 financial results, highlighting a cash position of $69.7 million and progress in its tegoprubart clinical program. The company remains on track to initiate its global Phase 3 LEGACY trial in kidney transplantation in Q4 2026 and recently received FDA Fast Track designation for the candidate.

Term
Q3 2026

“We continue to execute across our key strategic priorities and make meaningful progress in the tegoprubart clinical program across multiple transplant types, including plans to initiate our global Phase 3 LEGACY trial in kidney transplantation by year end.”

David-Alexandre C. Gros, M.D., Chief Executive Officer
4:10 PM ET 10-Q
Financial Results Fossil Group, Inc. FOSL

Fossil Group Q3 2026 Results: Turns Profitable, Net Income $11.4M

For the 13 weeks ended October 3, 2026, Fossil Group reported net sales of $271.2 million and net income attributable to the company of $11.7 million, a significant recovery from the $39.9 million loss in the prior year period. For the 39-week period, the company achieved a narrow net income of $0.2 million compared to a $59.7 million loss in 2025, driven by improved gross margins and reduced operating expenses.

Key figure
Net income $11.4M
4:10 PM ET 10-Q
Financial Results Shimmick Corp SHIM

Shimmick Q3 2026 Results: Turns Profitable, Net Income $848K

Shimmick Corporation reported a net income of $0.8 million for the third quarter of 2026, a significant improvement from a $4.4 million loss in the prior year period, despite a slight decrease in revenue to $135.8 million. For the nine months ended October 2, 2026, the company reduced its net loss to $8.4 million compared to $22.5 million in 2025, driven by improved gross margins and equity in earnings from joint ventures.

Key figure
Net income $848K
4:10 PM ET 8-K
Financial Results Arcadia Biosciences, Inc. RKDA

Arcadia Biosciences Financial Results

Arcadia Biosciences reported third-quarter 2026 financial results, highlighted by a 24% year-over-year increase in total revenues to $1.6 million. The growth was primarily driven by record quarterly sales for the Zola coconut water brand, which benefited from strong summer promotional programs and expanded distribution.

Term
Q3 2026

“The third quarter was very strong for Zola® with revenues growing 24% compared to the same quarter last year, resulting in the highest quarterly sales the brand has ever reported.”

T.J. Schaefer, CEO of Arcadia

“We are extremely excited to begin shipping our newly formulated espresso flavor this month after receiving pre-launch commitments from several of our leading customers.”

T.J. Schaefer, CEO of Arcadia
4:10 PM ET 10-Q
Financial Results Binah Capital Group, Inc. BCG

Binah Capital Group Q3 2026 Results: Net Income $2.65M, Up 50.3% YoY

Binah Capital Group reported a significant increase in net income to $4.89 million for the nine months ended September 30, 2026, compared to $2.14 million in the prior year period. Total revenues grew to $145.8 million, driven primarily by higher commission and advisory fee income, while the company maintained a strong cash position of $13.2 million.

Key figure
Net income $2.65M · +50.3% YoY
4:10 PM ET 10-Q
Financial Results Middleby Corp MIDD

Middleby Q3 2026 Results: Net Loss of $1.61M, Loss Narrows

Middleby Corp reported net sales of $1.90 billion for the first nine months of 2026, up from $1.75 billion in the prior year, though net earnings were significantly impacted by a $129.1 million loss from discontinued operations. The company completed the Midera spin-off during the period, resulting in a $780.2 million reduction in stockholders' equity.

Key figure
Net loss $1.61M
4:10 PM ET 10-Q
Financial Results Sunshine Silver Mining & Refining Co SSMR

Sunshine Silver Mining & Refining Q3 2026 Results: Net Loss of $20.9M, Loss Widens

Sunshine Silver Mining & Refining Company completed its IPO in June 2026, raising $291.9 million in net proceeds, significantly strengthening its cash position to $261.4 million. The company reported a net loss of $50.9 million for the nine months ended September 30, 2026, driven primarily by increased pre-development and general administrative expenses as it scales operations.

Key figure
Net loss $20.9M
4:10 PM ET 10-Q
Financial Results TriplePoint Private Venture Credit Inc.

TriplePoint Private Venture Credit Q3 2026 Results: Net Income $20.2M, Up 577.6% YoY

TriplePoint Private Venture Credit Inc. reported a significant turnaround for the nine months ended September 30, 2026, with a net increase in net assets resulting from operations of $39.5 million compared to a $3.0 million loss in the prior year period. This improvement was primarily driven by $34.2 million in net change in unrealized gains on investments, despite a slight decrease in total investment income.

Key figure
Net income $20.2M · +577.6% YoY

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.